Nanotechnology: A Key Enabler of Personalized Medicine
Linda K. Molnar
Office of Technology and Industrial Relations
National Cancer Institute
Dr. Linda Molnar currently serves as a Program Officer in the Office of Technology and Industrial Relations (OTIR) in the Office of the Director at the National Cancer Institute (NCI). In her role, she supports the management of grants and contracts for nanotechnology applications in cancer research for the NCI Alliance in Cancer Nanotechnology. She has a breadth of experience in collaborations and partnerships between academic institutions, large companies and biotechnology start-ups for the successful translation of fundamental research into applications and products. At NCI, she was instrumental in the successful launch of the Alliance in 2005. She has also led the formation of a clinical translation working group comprised of extramural investigators from the Alliance as well as internal NCI experts organized to address gaps in the clinical translation of nanotechnologies.
Her background includes the research and development of nanotechnology in a variety of applications and employments including Rohm and Haas Company, Caliper Technologies, and the NASA Ames Research Center. She received her Ph.D. in Materials Science and Engineering from the Massachusetts Institute of Technology and her B.S. in Chemistry with Honors from the University of Pittsburgh (magna cum laude). Dr. Molnar has also completed the Wharton Executive Management Program. She is frequently invited to speak on a range of topics in nanotechnology and nanomedicine from both a technical and a business perspective.
Speaking in the special symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment.